Group 1 - The China Securities Regulatory Commission (CSRC) has received a report from CITIC Securities regarding the initial public offering (IPO) and listing guidance for Bailin Pharmaceutical Technology (Shanghai) Co., Ltd. [1][11] - Bailin Pharmaceutical is a high-tech enterprise located in Shanghai, focusing on providing process solutions for the life sciences sector, including the development and manufacturing of key process equipment and consumables for recombinant protein drugs, vaccines, antibody drugs, cell therapy, gene therapy, and other biological products [1][11] - The company was established on September 10, 2021, with a registered capital of 360 million yuan [4][14] Group 2 - The controlling shareholder of Bailin Pharmaceutical is Hainan Bailin Technology Investment Center (Limited Partnership), which holds 100,068,120 shares, accounting for 27.7967% of the company [5][12] - Bailin Pharmaceutical has received investments from various institutions, including Shenzhen Capital Group, K2VC, Qingsong Capital, and Sherpa Capital [2][12] Group 3 - The guidance agreement for the IPO was signed on February 24, 2026, with CITIC Securities as the guiding institution, Beijing Jingtian & Gongcheng Law Firm as the legal advisor, and Rongcheng Certified Public Accountants as the accounting firm [6][15][16] - The guidance work includes comprehensive due diligence on the company's historical development, training on relevant laws and regulations, and preparation for compliance with listing requirements [7][16]